Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study evaluated changes in body fat distribution in human immunodeficiency virus type 1
(HIV-1) infected participants who either switched from a zidovudine- plus lamivudine-
containing highly active antiretroviral therapy (HAART) regimen to a regimen containing
Truvada® (a fixed-dose combination tablet of emtricitabine [FTC, 200 mg] and tenofovir
disoproxil fumarate [TDF, 300 mg]) or who remained on a zidovudine- plus
lamivudine-containing regimen. Subjects continued their protease inhibitor (PI) or
nonnucleoside reverse transcriptase inhibitor (NNRTI).
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lamivudine Zidovudine